Skip to content
Advertisement

FILE - In this Thursday, Dec.18, 2014, file photograph, scientist Christopher Kistler checks on experiments in AMBR250 bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. The bio-reactors allow a large number of experiments to be done in the lab at the same time. On Tuesday, June 27, 2017, Merck & Co. said a new type of cholesterol drug, in testing for many years, reduced heart attacks, deaths and other complications of heart disease in a huge late-stage study. (AP Photo/Mel Evans, File)

FILE - In this Thursday, Dec.18, 2014, file photograph, scientist Christopher Kistler checks on experiments in AMBR250 bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. The bio-reactors allow a large number of experiments to be done in the lab at the same time. On Tuesday, June 27, 2017, Merck & Co. said a new type of cholesterol drug, in testing for many years, reduced heart attacks, deaths and other complications of heart disease in a huge late-stage study. (AP Photo/Mel Evans, File)

Featured Photo Galleries